GANXライブシグナル | Getagraph.comで利益を最大化

Live Chart Being Loaded With Signals

Commentary (30 4月 2024 @ 01:45):

Stats
本日の出来高	24 373.00
平均出来高	162 204
時価総額	48.82M
EPS	$0 ( 2024-03-28 )
次の収益日	( $-0.300 ) 2024-05-10
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-1.760
ATR14	$0.0230 (0.76%)

Insider Trading

Date	Person	Action	Amount	type
2024-04-08	Mack Gene	Buy	200 000	Employee Stock Option (right to buy)
2024-04-05	Mack Gene	Buy	0
2024-03-28	Riley Jeffrey Scott	Buy	30 000	Common Stock
2024-03-26	Alder Matthias	Sell	18 750	Restricted Stock Units
2024-03-26	Alder Matthias	Buy	637	Common Stock

INSIDER POWER
86.82
Last 62 transactions
Buy: 1 996 906 \| Sell: 408 942

ボリューム相関

長: 0.16 (neutral)

短: -0.52 (weak negative)

Signal:(55.079) Neutral

Gain Therapeutics, Inc. 相関

10 最も正の相関
EMLD	0.95
ARRW	0.946
FTAA	0.937
OXAC	0.934
BCOR	0.933
HCVI	0.933
ARDX	0.932
MSAC	0.931
ADAL	0.93
FWAC	0.93

10 最も負の相関
BFC	-0.941
VORB	-0.926
BMRA	-0.923
ZSAN	-0.922
ORPH	-0.922
YJ	-0.92
EVLO	-0.92
CUTR	-0.919
HALO	-0.919
GRIN	-0.919

知っていましたか？

相関は、2つの変数間の関係を説明する統計的指標です。相関係数は-1から1までの値を取り、-1は完全な負の相関（1つの変数が増加すると、もう一方は減少する）、1は完全な正の相関（1つの変数が増加すると、もう一方も増加する）、0は相関がないことを示します（変数間に関係がない）。

相関は、株式だけでなく、どの2つの変数間の関係にも適用できます。これは、金融、経済学、心理学などの分野で一般的に使用されています。

Gain Therapeutics, Inc. 相関 - 通貨/商品

-0.27
( neutral )

-0.28
( neutral )

0.00
( neutral )

-0.21
( neutral )

0.62
( weak )

0.29
( neutral )

Gain Therapeutics, Inc. 財務諸表

Annual	2023
収益:	$55 180.00
総利益:	$-25 202.00 (-45.67 %)
EPS:	$-1.710

FY	2023
収益:	$55 180.00
総利益:	$-25 202.00 (-45.67 %)
EPS:	$-1.710

FY	2022
収益:	$140 108
総利益:	$75 940.00 (54.20 %)
EPS:	$-1.480

FY	2021
収益:	$164 994
総利益:	$0.00 (0.00 %)
EPS:	$-2.37

Financial Reports:

No articles found.

Gain Therapeutics, Inc.

Gain Therapeutics, Inc., a biotechnology company, engages in developing various therapies to treat diseases caused by protein misfolding. It focuses on rare genetic diseases and neurological disorders. The company uses its Site-Directed Enzyme Enhancement Therapy platform to discover allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites, restore protein folding, and treat disease. It is developing structurally targeted allosteric regulator candidates to treat various diseases, including Morquio B, GM1 gangliosidosis (GM1), neuronopathic Gaucher disease, GBA1 Parkinson's, Krabbe, and Mucopolysaccharidosis type 1 diseases. The company was founded in 2017 and is based in Bethesda, Maryland.